¶ Investment Landscape: RNA-Based Therapeutics for Neurodegenerative Diseases
Investment Landscape: RNA-Based Therapeutics covers the current R&D investment, clinical trial pipeline, and funding trends for RNA-based therapeutic approaches in neurodegenerative diseases including Alzheimer's Disease, Parkinson's Disease, ALS, Frontotemporal Dementia, and Huntington's Disease.
Last updated: 2026-03-17 14:50 PT
Total Clinical Trials: 187
Active Trials (Recruiting/Active): 42
| Phase |
Count |
| PHASE1 |
28 |
| PHASE1, PHASE2 |
15 |
| PHASE2 |
31 |
| PHASE2, PHASE3 |
4 |
| PHASE3 |
12 |
| PHASE4 |
3 |
| NA |
94 |
| Status |
Count |
| RECRUITING |
24 |
| ACTIVE_NOT_RECRUITING |
11 |
| NOT_YET_RECRUITING |
7 |
| COMPLETED |
89 |
| TERMINATED |
18 |
| WITHDRAWN |
8 |
- Antisense Oligonucleotides (ASO): 67 trials
- RNA Interference (RNAi): 23 trials
- MicroRNA-based therapies: 18 trials
- mRNA therapeutics: 12 trials
- Aptamers: 4 trials
- Splice-modulating RNAs: 12 trials
RNA therapeutics for AD remain in early-stage development compared to small molecule and antibody approaches. Key targets include:
- Tau pathology: BIIB080 (IONIS-MAPT) - Phase 1/2
- Amyloid precursor protein (APP): Various ASO approaches in preclinical
- APOE4: Gene silencing strategies under development
Current AD trials using RNA approaches: 31 trials (6.3% of total AD pipeline of ~4,910 trials)
RNA therapeutics in PD focus on:
- alpha-Synuclein: ASO and RNAi approaches targeting SNCA gene
- LRRK2: Genetic approaches for LRRK2-associated PD
- GBA1: Gene therapy for Gaucher's-associated PD
Current PD trials: 24 trials (4.8% of total PD pipeline)
ALS has the most advanced RNA therapeutic pipeline:
- Tofersen (BIIB067): Approved for SOD1-ALS
- WVE-004: C9orf72-targeting ASO - Phase 1/2
- ATXN2: Targeting ATXN2 expansion - Phase 1/2
- FUS: FUS-ALS ASO approaches in development
Current ALS trials: 52 trials (significantly higher proportion relative to disease size)
RNA approaches for FTD are emerging:
- C9orf72: Shared target with ALS - ASO in development
- MAPT: Tau-targeting ASOs for 4R-tauopathies
- GRN: Progranulin-modulating approaches
Current FTD trials: 18 trials
RNA therapeutics represent a major investment area for HD:
- Tominersen (RG6042/IONIS-HTTRx): Phase 3 completed, program restructure
- ASO targeting HTT: Multiple programs in development
- Allele-selective approaches: Exploring selective silencing of mutant HTT
Current HD trials: 42 trials
RNA-based therapeutics represent approximately 3.8% of the total neurodegenerative disease clinical trial pipeline (187 out of ~4,910 for AD alone). While still a minority approach, RNA therapeutics have shown promise in other neurological conditions and are attracting increasing investment.
- Genetic Target Specificity: RNA approaches enable precise targeting of disease-causing genetic mutations
- Disease-Modifying Potential: Unlike symptomatic treatments, RNA therapeutics can modify disease progression
- Blood-Brain Barrier Delivery: Current challenge - LNP and conjugate technologies improving CNS delivery
- Personalized Medicine: Potential for patient-specific ASO design based on genetic profiles
¶ Funding Landscape
Major pharmaceutical companies with active RNA neuroscience programs:
- Biogen: IONIS partnership, BIIB080, BIIB067 (Tofersen)
- Roche/Genentech: Tominersen partnership, C9orf72 programs
- Wave Life Sciences: WVE-004, WVE-003 (C9orf72, HTT)
- Alnylam: CNS delivery pipeline, ALN-APP for AD
- Ionis Pharmaceuticals: Broad CNS ASO pipeline
- NeuBase Therapeutics: PATrOL platform for CNS ASO delivery
| Year |
Key Investments |
| 2023 |
Biogen B+ Ionis expansion, Wave Life Sciences 00M+ financing |
| 2024 |
Roche continued C9orf72 investment, multiple Phase 1/2 readouts |
| 2025 |
Wave Life Sciences positive Phase 1b data, Alnylam CNS entry |
Only 12 trials (6.4%) are in Phase 3, compared to 321 (6.5%) for Alzheimer's overall. This indicates a significant gap in late-stage clinical development for RNA approaches.
- BBB Delivery Technologies: Investment in LNP, GalNAc conjugates, and novel delivery systems for CNS
- Biomarker Development: Surrogate endpoints for RNA therapeutic efficacy
- Combination Approaches: RNA therapeutics combined with small molecules or antibodies
- Pediatric/Young-Onset: Earlier intervention opportunities in genetic forms
- alpha-Synuclein targeting: Only ~8 trials, despite central role in PD
- Multiple System Atrophy (MSA): Virtually no RNA therapeutic trials
- Dystrophia myotonica protein kinase (DMPK): Limited crossover to neurodegeneration
All cross-links validated as of 2026-03-17. Cross-links to the following pages confirmed: